Physician profile
Zaina N Al-Mohtaseb
NPI 1659506822
$636,073.50
in general payments reported to CMS, 2019-2025
30 companies · $162K in 2025
The $162K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $39K · 2021: $32K · 2022: $77K · 2023: $71K · 2024: $190K · 2025: $162K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $211K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $145K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $28K · Travel and Lodging: $18K · Food and Beverage: $11K · Long Term Medical Supply Or Device Loan: $7,615 · Honoraria: $1,778 · Education: $55.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $210,558.73 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $145,375.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $28,350.00 |
| Travel and Lodging | $18,220.64 |
| Food and Beverage | $11,133.92 |
| Long Term Medical Supply Or Device Loan | $7,614.85 |
| Honoraria | $1,777.78 |
| Education | $55.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $167,657.23 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $123,787.22 | 2019-2025 | Clareon, Centurion, Acrysof Iq Panoptix Uv Iol |
| Johnson & Johnson Surgical Vision, INC. | $67,621.91 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Star S4 Ir |
| Bausch & Lomb Americas INC. | $46,467.89 | 2022-2025 | Miebo, Xiidra, Lotemax Sm |
| Carl Zeiss Meditec, INC. | $42,838.63 | 2019-2025 | Visumax, Veracity Surgical, Mel 90 |
| Alcon Research LLC | $41,617.89 | 2019-2025 | Centurion, Tryptyr, Clareon |
| Allergan, INC. | $24,132.12 | 2019-2022 | |
| Beaver-Visitec International, INC. | $24,000.33 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19,009.11 | 2019-2021 | |
| Glaukos Corporation | $16,470.44 | 2022-2025 | Kxl System, Kxl System (Not Refurbished), Ce-Marked Kxla System |
| Novartis Pharmaceuticals Corporation | $13,199.04 | 2019-2022 | |
| Abbvie INC. | $13,073.45 | 2022-2025 | Vuity, Alphagan P, Lumigan |
| Ocular Therapeutix, INC. | $9,731.42 | 2019-2025 | Dextenza |
| Dompe US, INC. | $9,462.88 | 2020-2025 | Oxervate |
| Rxsight INC | $5,072.90 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $4,348.31 | 2019 | |
| Harrow Eye, LLC | $1,881.27 | 2024-2025 | Vevye |
| Thea Pharma INC. | $1,472.85 | 2022-2023 | |
| Eyevance Pharmaceuticals LLC | $1,340.78 | 2019 | |
| Kala Pharmaceuticals, INC. | $1,037.80 | 2019 | |
| Sun Pharmaceutical Industries INC. | $659.78 | 2019-2025 | Cequa, Bromsite, Xelpros |
| Carl Zeiss Meditec USA, INC. | $602.20 | 2021-2024 | |
| Oyster Point Pharma, INC. | $149.01 | 2023-2024 | Tyrvaya, Ryzumvi |
| Biotissue Holdings INC. | $97.63 | 2022-2025 | |
| Omeros Corporation | $77.90 | 2019-2020 | |
| Carl Zeiss Meditec Production LLC | $69.03 | 2019 | |
| Amgen INC. | $58.80 | 2024-2025 | Tepezza |
| Sight Sciences, INC. | $58.54 | 2023-2025 | Tearcare System, Omni Surgical System |
| Astellas Pharma US INC | $45.78 | 2024 | Izervay |
| Tearlab Corp | $31.36 | 2023 | Tearlab Osmolarity System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zaina Al-Mohtaseb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.